Details of the Drug Combination

General Information of Drug Combination (ID: DC9HD1Z)

Drug Combination Name
Tazemetostat Umbralisib
Indication
Disease Entry Status REF
Recurrent Follicular Lymphoma Phase 1 [1]
Component Drugs Tazemetostat   DMWP1BH Umbralisib   DMYRBO1
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Tazemetostat
Disease Entry ICD 11 Status REF
Follicular lymphoma 2A80 Approved [2]
Brain and central nervous system tumour 2A00.11 Phase 2 [3]
Malignant rhabdoid tumour 2A00.1Y Phase 2 [4]
Mesothelioma 2C51.2 Phase 2 [5]
Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
Diffuse large B-cell lymphoma 2A81 Phase 1/2 [5]
Synovial sarcoma 2B5A Phase 1 [5]
Tazemetostat Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Enhancer of zeste homolog 2 (EZH2) TT9MZCQ EZH2_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Umbralisib
Disease Entry ICD 11 Status REF
Follicular lymphoma 2A80 Approved [6]
Marginal zone lymphoma 2A85.0 Approved [6]
Diffuse large B-cell lymphoma 2A81 Phase 2/3 [7]
Chronic lymphocytic leukaemia 2A82.0 Phase 2 [5]
Non-hodgkin lymphoma 2B33.5 Phase 2 [5]
Umbralisib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [6]
Casein kinase I epsilon (CSNK1E) TTA8PLI KC1E_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05152459) Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
7 ClinicalTrials.gov (NCT02793583) Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL). U.S. National Institutes of Health.